CRY-12443-29041
2 vaccinations
3 coded responses
25 check-ins
3 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 41-45
- ZIP prefix
- 921 / CA
- Registered
- 2020-12-27
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-27
Registered in v-safe
-
2020-12-27
Dose 1 — Pfizer-BioNTech
- 2020-12-27
- 2020-12-28
- 2020-12-29
- 2020-12-30
- 2020-12-31
- 2021-01-01
- 2021-01-02
- 2021-01-03
- 2021-01-10
-
2021-01-19
Dose 2 — Pfizer-BioNTech
-
2021-01-19
Survey response — day 0, dose 2MedDRA: Tension headache — Feeling: Good · Site: Pain · HeadacheFree text: Had mild-moderate tension headache prior to receiving vaccine. Waited til after vaccine to take APAP several hours after vaccine.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-20
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Headache, Muscle or body aches · Be unable to do your normal daily activitiesAdult check-in
- 2021-01-21
- 2021-01-22
- 2021-01-23
- 2021-01-24
- 2021-01-25
- 2021-01-28
-
2021-02-02
Survey response — day 14, dose 2MedDRA: Headache, Migraine with aura, Visual impairment — Feeling: Good · Be unable to work, Be unable to do your normal daily activitiesFree text: Severe Migraine with aura - visual disturbances lasted 6 hrs (blurry/spotty vision, seeing electrified black/white zigzags) and included losing the ability to read and comprehend written/typed words. HA lasted ~24-30 hrs. Still sensitive to light.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-09
Survey response — day 21, dose 2MedDRA: Migraine, Photophobia — Feeling: GoodFree text: Residual visual light sensitivity after 1/30 migraine that was different than other migraines in past. Light sensitivity lasted through 2/3/21.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-02-16
- 2021-02-23
- 2021-03-02
- 2021-04-20
- 2021-07-20
- 2022-01-21
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-27 | Pfizer-BioNTech | |
| 2 | 2021-01-19 | Pfizer-BioNTech |
Free text
Release 2 — day 0, dose 2
Systemic reaction (other): Had mild-moderate tension headache prior to receiving vaccine. Waited til after vaccine to take APAP several hours after vaccine.
Release 3 — day 14, dose 2
Symptoms: Severe Migraine with aura - visual disturbances lasted 6 hrs (blurry/spotty vision, seeing electrified black/white zigzags) and included losing the ability to read and comprehend written/typed words. HA lasted ~24-30 hrs. Still sensitive to light. cut off by CDC
Release 3 — day 21, dose 2
Symptoms: Residual visual light sensitivity after 1/30 migraine that was different than other migraines in past. Light sensitivity lasted through 2/3/21.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Headache | ✓ | ✓ | ✓ |
| SD | Migraine | ✓ | ✓ | ✓ |
| SD | Migraine with aura | ✓ | ✓ | ✓ |
| SD | Photophobia | ✓ | ✓ | ✓ |
| SD | Visual impairment | ✓ | ✓ | ✓ |
| SRO | Tension headache | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release